ClinicalTrials.Veeva
Menu

Find clinical trials for Leukemia in Detroit, MI

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Myeloid Leukemia
Acute Myeloid Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma
Myelodysplastic Syndromes

Leukemia trials near Detroit, MI, USA:

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: Ziftomenib

Phase 1, Phase 2

Kura Oncology

Detroit, Michigan, United States and 51 other locations

The overarching objective of this study is to use novel precision medicine strategies based on inherited and acquired leukemia-specific geno...

Active, not recruiting
Acute Lymphoblastic Leukemia
Acute Lymphoblastic Lymphoma
Drug: Asparaginase Erwinia chrysanthemi (recombinant)-rywn
Drug: Thioguanine

Phase 2, Phase 3

St. Jude Children's Research Hospital
St. Jude Children's Research Hospital

Detroit, Michigan, United States and 7 other locations

chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...

Active, not recruiting
Leukemia
Drug: Methotrexate
Drug: Thioguanine

Phase 2

Incyte
Incyte

Ann Arbor, Michigan, United States and 110 other locations

Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib ...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Gilteritinib
Drug: Daunorubicin

Phase 2

PrECOG

Ann Arbor, Michigan, United States and 43 other locations

The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participan...

Active, not recruiting
Myeloid Leukemia, Chronic, Chronic Phase
Drug: Ponatinib

Phase 2

Takeda
Takeda

Detroit, Michigan, United States of America and 85 other locations

This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN...

Active, not recruiting
Acute Myeloid Leukemia
Drug: IMGN632
Drug: Venetoclax

Phase 1, Phase 2

ImmunoGen
ImmunoGen

Ann Arbor, Michigan, United States and 30 other locations

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retr...

Enrolling
Chronic Lymphocytic Leukemia (CLL)
Drug: Venetoclax
Drug: Obinutuzumab

Phase 2

AbbVie
AbbVie

Detroit, Michigan, United States and 49 other locations

Ozogamicin(GO) in subjects with relapsed/refractory acute myeloid leukemia. Using a standard 3+3 design, subjects will receive once cycle of...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Venetoclax
Drug: Gemtuzumab Ozogamicin

Phase 1

John Quigley

Ann Arbor, Michigan, United States and 3 other locations

with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML) who are refractory to or have relapsed after first-line AML therap...

Active, not recruiting
Leukemia, Acute Myeloid (AML)
Drug: MEC (Mitoxantrone, Etoposide, Cytarabine)
Drug: gilteritinib

Phase 3

Astellas
Astellas

Detroit, Michigan, United States and 125 other locations

of a study drug called fedratinib in participants with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) and chronic neutrophilic leukemia...

Active, not recruiting
Chronic Neutrophilic Leukemia
MDS
Drug: Fedratinib Pill

Phase 2

H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute

Ann Arbor, Michigan, United States and 2 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems